An open-label trial of nefazodone in high comorbidity panic disorder

Journal of Clinical Psychiatry

Volumn 57, Issue 6, 1996, Pages 245-248

  DeMartinis, Nicholas A ^a   Schweizer, Edward ^a   Rickels, Karl ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEFAZODONE;

ADULT; ANXIETY NEUROSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DYSTHYMIA; FATIGUE; FEMALE; HUMAN; MALE; MORBIDITY; NAUSEA; PANIC; PRIORITY JOURNAL; SOMNOLENCE; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; COMORBIDITY; DEPRESSION; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; PANIC DISORDER; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRIAZOLES;

EID: 0030015454     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Robins LN, Regier DA. Psychiatric Disorders in America. New York, NY: The Free Press; 1991
2. Boyd JH, Burke JD, Gruenberg E, et al. Exclusion criteria of DSM-III: a study of co-occurrence of hierarchy-free syndromes. Arch Gen Psychiatry 1984;41:983-989
3. Breier A, Charney DS, Heninger GR. Agoraphobia with panic attacks. Arch Gen Psychiatry 1986;43:1029-1036
4. Brown TA, Barlow DH. Comorbidity among anxiety disorders: implications for treatment and DSM-IV. J Consult Clin Psychol 1992;60(6): 835-844
5. Ballenger JC, Burrows GD, DuPont RL Jr, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial, I: efficacy in short-term treatment. Arch Gen Psychiatry 1988;45:413-422
6. Noyes R Jr, Reich J, Christiansen J, et al. Outcome of panic disorder: relationship to diagnostic subtypes and comorbidity. Arch Gen Psychiatry 1990;47:809-818
7. Keller MB, Lavori PW, Goldenberg IM, et al. Influence of depression on the treatment of panic disorder with imipramine, alprazolam, and placebo. J Affect Disord 1993;28:27-38
8. Eison AS, Eison MS, Torrente JR, et al. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacology (Berl) 1990;26: 311-315
9. Rickels K, Schweizer E, Clary C, et al. Nefazodone and imipramine in major depression: a placebo controlled trial. Br J Psychiatry 1994;164: 802-805
10. Fontaine R, Ontiveros A, Elie R, et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994;55:234-241
11. Mavissakalian M, Perel J, Bowler K, et al. Trazodone in the treatment of panic disorder. Am J Psychiatry 1987;144:785-787
12. Charney DS, Woods SW, Goodman WK, et al. Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry 1986;47:580-586
13. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder: a placebo controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993;50: 884-895
14. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
16. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
17. Sheehan DV. The Anxiety Disease. New York, NY: Bantam Books; 1986
18. Schweizer E, Rickels KR, Weiss S, et al. Maintenance drug treatment of panic disorder, I: results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry 1993;50:51-60
19. Mavissakalian MR, Perel JM. Imipramine treatment of panic disorder with agoraphobia: dose ranging plasma level response relationships. Am J Psychiatry 1995;152:673-682
20. Cross National Collaborative Panic Study Second Phase Investigators. Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine, and placebo. Br J Psychiatry 1992;160:191-202